| Dr William Scott Walters, MD | |
|
1015 Medical Center Pkwy, Selma, AL 36701-6748 | |
| (251) 342-5646 | |
| Not Available |
| Full Name | Dr William Scott Walters |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 30 Years |
| Location | 1015 Medical Center Pkwy, Selma, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366400111 | NPI | - | NPPES |
| 051520765 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 046511 (Georgia) | Secondary |
| 207P00000X | Emergency Medicine | 19686 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center Barbour | Eufaula, AL | Hospital |
| Bullock County Hospital | Union springs, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Professional Resources Management, Inc. | 5597748350 | 6 |
| Southland Medical Solutions Of Eufaula, Pl | 1951469410 | 4 |
News Archive
Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.
Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.
KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.
› Verified 3 days ago
| Entity Name | Professional Resources Management, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992812382 PECOS PAC ID: 5597748350 Enrollment ID: O20040611000549 |
News Archive
Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.
Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.
KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.
› Verified 3 days ago
| Entity Name | Southland Medical Solutions Of Eufaula, Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205092723 PECOS PAC ID: 1951469410 Enrollment ID: O20081028000262 |
News Archive
Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.
Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.
KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.
› Verified 3 days ago
| Entity Name | Moore Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013415769 PECOS PAC ID: 9537421516 Enrollment ID: O20180403002099 |
News Archive
Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.
Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.
KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.
› Verified 3 days ago
| Entity Name | The Health Care Authority Of The City Of Eufaula |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730692641 PECOS PAC ID: 9335407659 Enrollment ID: O20180619000582 |
News Archive
Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.
Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.
KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.
› Verified 3 days ago
| Entity Name | Ess Of Eufaula, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013650456 PECOS PAC ID: 0840677456 Enrollment ID: O20220520001733 |
News Archive
Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.
Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.
KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Scott Walters, MD 200 Corporate Blvd, Suite 201, Lafayette, LA 70508-3870 Ph: (800) 893-9698 | Dr William Scott Walters, MD 1015 Medical Center Pkwy, Selma, AL 36701-6748 Ph: (251) 342-5646 |
News Archive
Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.
Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.
KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.
› Verified 3 days ago
Tessa Fain, PA Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1015 Medical Center Pkwy, Selma, AL 36701 Phone: 334-418-4100 | |
Phillip Hicks, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1015 Medical Center Pkwy, Selma, AL 36701 Phone: 800-893-9698 | |
Dr. Cesar Arthro Ravelo, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1015 Medical Center Pkwy, Selma, AL 36701 Phone: 334-270-9793 | |
Dr. Jose Antonio Lopez-lago, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1015 Medical Center Pkwy, Selma, AL 36701 Phone: 706-582-2393 | |
Dr. Sean Brian Bohannon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 203 Vaughan Memorial Dr, Selma, AL 36701 Phone: 334-375-8007 Fax: 334-526-1849 |